Cancer cachexia in thoracic malignancy: a narrative review.

Area of Science:

• Oncology
• Metabolism
• Radiology

Background:

• Thoracic malignancies are highly lethal cancers.
• Cancer cachexia is defined as ongoing skeletal muscle mass loss (sarcopenia) with or without fat mass loss, leading to functional impairment.
• The syndrome lacks universally accepted diagnostic criteria.

Purpose of the Study:

• To review current evidence on cancer cachexia in thoracic malignancies.
• To summarize imaging techniques for sarcopenia assessment.
• To discuss inflammatory and metabolic changes and potential treatments.

Main Methods:

• Literature review of current evidence.
• Analysis of imaging techniques for sarcopenia.
• Examination of inflammatory and metabolic alterations.
• Review of ongoing treatment research.

Main Results:

• Sarcopenia is a key component of cancer cachexia, prevalent in non-small cell lung cancer (NSCLC).
• Patients with sarcopenia experience increased treatment side effects and reduced survival.
• Current diagnostic criteria for cancer cachexia are not universally accepted.

Conclusions:

• Early identification of cancer cachexia is vital for risk stratification and intervention.
• Emerging anti-cachexia treatments may improve treatment tolerance, quality of life, and survival.
• Further research into sarcopenia and cachexia treatments is warranted for thoracic malignancy patients.